– USA, NC – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced the appointment of Raj Kannan to its Board of Directors as CEO, effective December 20, 2021.
“I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S. and globally, building commercial operations, providing strategic direction to pipeline development and successfully guiding companies through important inflections in their growth trajectories,” said Executive Chairman, Dr. Ben McGraw.
Dr. McGraw added, “With a strong commercial franchise in glaucoma, solid research and development foundation, and a pipeline led by two-Phase 3-ready programs, Aerie is poised to fulfill its goal of becoming a leading ophthalmology company under Raj’s thoughtful and strategic leadership.”
About Raj Kannan
Raj Kannan has over 25 years of experience leading and developing companies. He has effectively led and grown organizations and supported multiple successful launches across therapeutic areas in the U.S. and globally. Before joining Aerie, Raj was the CEO and President of Chiasma, Inc., where he led the organization through the approval and the launch of the first oral therapy in over a decade for patients with acromegaly and subsequently through the acquisition by Amryt Pharma Plc. Before that, Raj was Chief Commercial Officer at Kiniksa Pharmaceuticals, Ltd., where he built the commercial operations, including sales, marketing, and business analytics functions. Before Kiniksa, Raj served as the Global Head of the Neurology and Immunology business franchise at Merck KGaA, where he was responsible for transforming the largest franchise into a growing franchise with $2B in annual revenues through significant strategic shifts in investment to support new product introductions and through the recalibration of pipeline investments. Before that, Raj spent ten years at Boehringer Ingelheim International GmbH in the U.S., Canada, and Germany, including as Global Marketing Head of the Cardiovascular Franchise, where he was responsible for more than $3.5B in annual revenues. Raj currently serves as a non-executive board member for Amryt Pharma Plc.
“The Aerie team has built an impressive ophthalmology company with an exciting glaucoma franchise that is global in reach and an exciting pipeline of product development candidates that has the potential to create significant value. I am honored to have this opportunity to lead the company and work with this team to deliver on our commercial prospects and realize the full promise of our pipeline,” said CEO, Raj Kannan.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class/best-in-class therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration. Aerie has two approved products, two Phase 3-ready programs, and an ongoing research program.
For more information: https://aeriepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.